Search PeptideClear
Peptides, vetted UK sellers, or GLP-1 clinics. Pick a tab below.
Try a quick search
We have not vetted that site yet.
PeptideClear can audit this source for you for free. Editorial verdict within 72 hours.
Got it. Editorial verdict within 72 hours.
We will email you a link to the published /retailer/[slug]/ profile once the audit lands.
While you wait, 3 already-vetted alternatives
Alternatives are matched to your stated goal. We earn nothing if you click through, and the links carry no tracking. How we are funded.
Regulatory tracker
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-07-13
The MHRA published 24 items in the 90 days to 2026-07-13, of which 3 relate to weight-loss medicines or peptides, 3 concern enforcement against illegal or unlicensed supply, and 4 are formal Drug Safety Updates. This page restates what the regulator published and links to each gov.uk original. It is a reporting record, not advice. If a medicine you take appears in a Drug Safety Update, the item itself tells you what the MHRA asks patients and prescribers to do, and your prescriber or pharmacist is the person to speak to.
24
MHRA items in the window
3
Relevant to this site
3
Enforcement actions
4
Drug Safety Updates
The subset that touches the categories this site covers. Everything else the regulator published in the same window is in the full table below.
The semaglutide injection has been approved to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis.
Read the MHRA original on gov.ukThe MHRA, Advertising Standards Authority, and the General Pharmaceutical Council have issued a warning to businesses seeking to promote newly authorised medicines, as well as those that do not yet have a marketing authorisa.
Read the MHRA original on gov.ukHaving met the MHRA’s rigorous standards of safety, quality and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and weight management.
Read the MHRA original on gov.ukEverything the MHRA published between 2026-04-30 and 2026-07-10, newest first. We list the full record rather than only the convenient parts, so the selection above can be checked against what was actually published.
| Date | Type | Item | Relevant to weight-loss medicines or peptides |
|---|---|---|---|
| 2026-07-10 | Announcement | Yellow Cards: bad in football; brilliant in patient safety | No |
| 2026-07-09 | Announcement | MHRA safety review gives UK plasma donations go ahead | No |
| 2026-07-09 | Announcement | Heat, travel and late nights: How summer can affect your medicines and how to stay safe | No |
| 2026-07-08 | Announcement | Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis | No |
| 2026-07-08 | Enforcement | Four sentenced to nearly 15 years combined jail time following major MHRA investigation into illegal online supply of medicines | No |
| 2026-07-06 | Announcement | MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer | No |
| 2026-07-03 | Announcement | Semaglutide (Wegovy) approved to treat form of liver disease | Yes |
| 2026-07-02 | Announcement | Making regulation a catalyst, not a barrier, for UK life sciences | No |
| 2026-07-01 | Enforcement | MHRA secures convictions after a decade-long investigation into falsely marked baby-feeding devices | No |
| 2026-07-01 | Announcement | MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer | No |
| 2026-06-19 | Announcement | Update on the PATHWAYS clinical trial | No |
| 2026-06-18 | Enforcement | Warning on promoting newly licensed prescription-only medicines and unlicensed medicines for weight management | Yes |
| 2026-06-16 | Drug safety update | ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly | No |
| 2026-06-15 | Announcement | Unique liaison programme set to reinforce close collaboration between MHRA and FDA | No |
| 2026-06-12 | Announcement | Lower dose needle-free allergy treatment approved for younger children | No |
| 2026-06-12 | Announcement | MHRA scientific leader recognised in 2026 King’s Birthday Honours | No |
| 2026-06-11 | Announcement | MHRA landmark report reveals public views on AI in healthcare | No |
| 2026-06-11 | Announcement | First GLP-1 tablet for weight loss approved in the UK | Yes |
| 2026-06-10 | Announcement | Pioneering AI health innovations regulatory sandbox launched | No |
| 2026-06-09 | Announcement | Nipocalimab (Imaavy) authorised to treat adults and adolescents with generalised myasthenia gravis | No |
| 2026-06-09 | Announcement | MHRA launches AI sandbox to accelerate medicines development and improve safety | No |
| 2026-05-20 | Drug safety update | Amiodarone: reminder of risks of treatment and need for patient monitoring and supervision | No |
| 2026-05-11 | Drug safety update | Finasteride and Dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction | No |
| 2026-04-30 | Drug safety update | Nasal decongestant sprays and drops containing xylometazoline hydrochloride / oxymetazoline hydrochloride: increased risk of rebound congestion, rhinitis medicamentosa, and tachyphylaxis with overuse | No |
Source: gov.uk MHRA announcements feed and MHRA Drug Safety Update feed
### MHRA items published in the 90 days to 2026-07-13, by date and type | Date | Type | Item | Relevant to weight-loss medicines or peptides | | --- | --- | --- | --- | | 2026-07-10 | Announcement | Yellow Cards: bad in football; brilliant in patient safety | No | | 2026-07-09 | Announcement | MHRA safety review gives UK plasma donations go ahead | No | | 2026-07-09 | Announcement | Heat, travel and late nights: How summer can affect your medicines and how to stay safe | No | | 2026-07-08 | Announcement | Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis | No | | 2026-07-08 | Enforcement | Four sentenced to nearly 15 years combined jail time following major MHRA investigation into illegal online supply of medicines | No | | 2026-07-06 | Announcement | MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer | No | | 2026-07-03 | Announcement | Semaglutide (Wegovy) approved to treat form of liver disease | Yes | | 2026-07-02 | Announcement | Making regulation a catalyst, not a barrier, for UK life sciences | No | | 2026-07-01 | Enforcement | MHRA secures convictions after a decade-long investigation into falsely marked baby-feeding devices | No | | 2026-07-01 | Announcement | MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer | No | | 2026-06-19 | Announcement | Update on the PATHWAYS clinical trial | No | | 2026-06-18 | Enforcement | Warning on promoting newly licensed prescription-only medicines and unlicensed medicines for weight management | Yes | | 2026-06-16 | Drug safety update | ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly | No | | 2026-06-15 | Announcement | Unique liaison programme set to reinforce close collaboration between MHRA and FDA | No | | 2026-06-12 | Announcement | Lower dose needle-free allergy treatment approved for younger children | No | | 2026-06-12 | Announcement | MHRA scientific leader recognised in 2026 King’s Birthday Honours | No | | 2026-06-11 | Announcement | MHRA landmark report reveals public views on AI in healthcare | No | | 2026-06-11 | Announcement | First GLP-1 tablet for weight loss approved in the UK | Yes | | 2026-06-10 | Announcement | Pioneering AI health innovations regulatory sandbox launched | No | | 2026-06-09 | Announcement | Nipocalimab (Imaavy) authorised to treat adults and adolescents with generalised myasthenia gravis | No | | 2026-06-09 | Announcement | MHRA launches AI sandbox to accelerate medicines development and improve safety | No | | 2026-05-20 | Drug safety update | Amiodarone: reminder of risks of treatment and need for patient monitoring and supervision | No | | 2026-05-11 | Drug safety update | Finasteride and Dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction | No | | 2026-04-30 | Drug safety update | Nasal decongestant sprays and drops containing xylometazoline hydrochloride / oxymetazoline hydrochloride: increased risk of rebound congestion, rhinitis medicamentosa, and tachyphylaxis with overuse | No | Source: gov.uk MHRA announcements feed and MHRA Drug Safety Update feed
“A rolling window is honest but it is not history. Items drop off this page after ninety days, so an absence here means the MHRA has not published on it recently, not that nothing has ever been published. Read the enforcement rows as evidence that illegal supply is actively prosecuted in the UK, and read a quiet period as ordinary rather than as reassurance about any particular seller.”
Last fetched 2026-07-13. PeptideClear is editorial. We do not prescribe, dispense or sell medicines.
PeptideClear is editorial. Nothing here replaces the regulator, and you should not take our word for any of it. These are the official UK destinations where the underlying position is published, free to read and open to anyone.
MHRA
MHRA Products portalThe Summary of Product Characteristics and Patient Information Leaflet for every medicine licensed in the UK. This is the authoritative document for what a medicine is licensed to do.
MHRA
Drug Safety UpdateThe MHRA monthly bulletin of safety advice for prescribers and patients. Where new risks and product information changes are formally announced.
MHRA
Report a fake or illegally supplied medicineThe MHRA route for reporting a website or seller supplying medicines illegally, and for reporting a product you believe is counterfeit.
Advertising Standards Authority
CAP Code and ASA rulingsThe UK advertising rules, including the ban on advertising prescription-only medicines to the public, and the published rulings that show how they are applied.
World Anti-Doping Agency
WADA Prohibited ListThe annually updated list of substances and methods banned in sport. Many research peptides sit under S0 or S2. UK Anti-Doping enforces it on tested athletes.
legislation.gov.uk
Human Medicines Regulations 2012The legislation that defines what counts as a medicine in the UK, and what constitutes illegal supply. A product marketed with medicinal claims is regulated as a medicine regardless of how it is labelled.
PeptideClear maintains these as refreshable datasets rather than one-off articles. Each carries its own source, methodology and last-updated date.
Live data tracker
UK GLP-1 prescribing tracker →
Monthly NHS England primary-care prescribing volumes for GLP-1 medications, rebuilt as each new month publishes. Dated chart, month-by-month table, full methodology.
Source: NHSBSA English Prescribing Dataset
Live data tracker
UK peptide clinical-trials tracker →
Registered interventional trials for every research peptide we track, by phase and recruitment status, linking through to each compound record.
Source: ClinicalTrials.gov and ISRCTN
Live data tracker
UK research-peptide price index →
Headline price per milligram across the UK research-peptide retailers we score, so a price can be read against the market rather than in isolation.
Source: PeptideClear retailer survey
Live data tracker
CoA Trust Index →
Forty UK sellers scored on six observable certificate-of-analysis signals. Green, amber and red tiers, with every signal reproducible from the published data.
Source: PeptideClear methodology
PeptideClear is a trading name of Best Business Loans Ltd, registered in England and Wales (company number 16833937). All services, operations and publications under the PeptideClear brand are delivered by Best Business Loans Ltd.
Registered in England and Wales. Company number 16833937. D‑U‑N‑S 234324824. ICO registered, reference ZC151816 (certificate, verify). Registered supplier on the UK Government's Find a Tender Service (FTS). Details publicly available via Companies House and OpenCorporates.
Operates under UK data protection and consumer standards. Aligns with UK GDPR, ISO 27001 and ISO 9001 principles. Working towards Cyber Essentials certification.
Primary domain peptideclear.co.uk. Business ownership, entity and services remain unchanged. Reviewed quarterly.